Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration

Patrizia Giannatempo, Gregory R. Pond, Guru Sonpavde, Costantine Albany, Yohann Loriot, Christopher J. Sweeney, Roberto Salvioni, Maurizio Colecchia, Nicola Nicolai, Daniele Raggi, Kevin R. Rice, Chandra K. Flack, Nemer R. El Mouallem, Hope Feldman, Karim Fizazi, Lawrence H. Einhorn, Richard S. Foster, Andrea Necchi, Clint Cary

Research output: Contribution to journalArticle

27 Scopus citations

Abstract

Purpose We assessed prognostic factors, treatments and outcomes in patients with teratoma with malignant transformation, a rare occurrence among germ cell tumors. Materials and Methods Data on patients diagnosed with teratoma with malignant transformation between June 1981 and August 2014 were collected across 5 referral centers. Chemotherapy was dichotomized as based on germ cell tumor or teratoma with malignant transformation. Cox analyses were done to evaluate prognostic factors of overall survival, the primary end point. Each factor was evaluated in a univariable model. Forward stepwise selection was used to construct an optimal model. Results Among 320 patients the tumor primary site was gonadal in 287 (89.7%), retroperitoneal in 17 (5.3%) and mediastinal in 16 (5%). Teratoma with malignant transformation and germ cell tumor were diagnosed concurrently in 130 patients (40.6%). A total of 49 patients (16.8%) initially presented with clinical stage I. The remaining patients were at good (123 or 42.3%), intermediate (42 or 14.4%) and poor (77 or 26.5%) risk for metastasis according to IGCCCG (International Germ Cell Cancer Collaborative Group). First line chemotherapy was given for germ cell tumor in 159 patients (49.7%), chemotherapy for teratoma with malignant transformation was performed in 14 (4.4%) and only surgery was done in 147 (45.9%). Median followup was 25.1 months (IQR 5.4–63.8). Five-year overall survival was 83.4% (95% CI 61.3 to 93.5) in patients with clinical stage I and it was also worse than expected in those with metastasis. On multivariable analyses nonprimitive neuroectodermal tumor histology (overall p = 0.004), gonadal primary tumor (p = 0.005) and fewer prior chemotherapy regimens (p <0.001) were independent predictors of better overall survival. Chemotherapy was not independently prognostic. Conclusions Less heavily pretreated teratoma with malignant transformation with a gonadal primary tumor and nonprimitive neuroectodermal tumor histology appears to be associated with longer overall survival. Generally, teratoma with malignant transformation had a worse prognosis than germ cell tumor. Uncertainties persist regarding optimal chemotherapy.

Original languageEnglish (US)
Pages (from-to)95-100
Number of pages6
JournalJournal of Urology
Volume196
Issue number1
DOIs
StatePublished - Jul 1 2016

Keywords

  • cell transformation, neoplastic
  • drug therapy
  • neoplasms, germ cell and embryonal
  • teratoma
  • testicular neoplasms

ASJC Scopus subject areas

  • Urology

Fingerprint Dive into the research topics of 'Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration'. Together they form a unique fingerprint.

  • Cite this

    Giannatempo, P., Pond, G. R., Sonpavde, G., Albany, C., Loriot, Y., Sweeney, C. J., Salvioni, R., Colecchia, M., Nicolai, N., Raggi, D., Rice, K. R., Flack, C. K., El Mouallem, N. R., Feldman, H., Fizazi, K., Einhorn, L. H., Foster, R. S., Necchi, A., & Cary, C. (2016). Treatment and Clinical Outcomes of Patients with Teratoma with Somatic-Type Malignant Transformation: An International Collaboration. Journal of Urology, 196(1), 95-100. https://doi.org/10.1016/j.juro.2015.12.082